Ubs Asset Management Americas Inc Gilead Sciences, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 10,628,942 shares of GILD stock, worth $955 Million. This represents 0.23% of its overall portfolio holdings.
Number of Shares
10,628,942
Previous 11,139,775
4.59%
Holding current value
$955 Million
Previous $764 Million
16.57%
% of portfolio
0.23%
Previous 0.22%
Shares
28 transactions
Others Institutions Holding GILD
# of Institutions
1,931Shares Held
991MCall Options Held
10.5MPut Options Held
9.75M-
Black Rock Inc. New York, NY121MShares$10.8 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$10.4 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$6.88 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$5.55 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.41 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $113B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...